Pain Therapeutics, Inc. (NASDAQ:PTIE) – Investment analysts at Gabelli raised their FY2017 earnings estimates for Pain Therapeutics in a research report issued to clients and investors on Wednesday. Gabelli analyst K. Kedra now expects that the biopharmaceutical company will earn ($1.90) per share for the year, up from their prior estimate of ($2.20). Gabelli also issued estimates for Pain Therapeutics’ FY2018 earnings at ($2.50) EPS, FY2019 earnings at ($5.00) EPS, FY2020 earnings at ($4.70) EPS and FY2021 earnings at ($3.50) EPS.

PTIE has been the subject of a number of other research reports. ValuEngine lowered Pain Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research lowered Pain Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 27th.

Shares of Pain Therapeutics (NASDAQ PTIE) opened at $7.80 on Friday. The stock has a market capitalization of $51.44, a P/E ratio of -4.24 and a beta of 2.11. Pain Therapeutics has a twelve month low of $3.10 and a twelve month high of $12.80.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter.

A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in Pain Therapeutics, Inc. (NASDAQ:PTIE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned approximately 0.91% of Pain Therapeutics as of its most recent SEC filing. 35.99% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/13/fy2017-eps-estimates-for-pain-therapeutics-inc-ptie-increased-by-analyst.html.

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Earnings History and Estimates for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.